VANCOUVER, BC, March 10, 2021 /CNW/ - Sirona Biochem
Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) is pleased to announce
the launch of the first commercial product containing the Company's
proprietary ingredient, TFC-1067. TFC-1067 will debut as the active
ingredient in New Rodan + Fields REVERSE Targeted Dark
Spot Corrector. It will precisely target stubborn discoloration
for a brighter, even-looking skin tone.
Rodan + Fields licensed TFC-1067 from Sirona in
2019.
In Rodan + Fields clinical trials*, REVERSE Targeted Dark Spot
Corrector had the following results:
- After 4 Weeks: 77% had less visible dark spots
- After 8 Weeks: 72% didn't feel like their dark spots
were the first thing people noticed
Rodan + Fields additional claims:
- Diminishes the appearance of stubborn dark spots without
leaving a halo
- Stubborn dark spots look smaller, less defined, less
intense
- Skin tone looks more uniform and even
- Stubborn dark spots are less visible, less noticeable
- Skin looks clearer, more translucent
Sirona also recently partnered with a top-ten pharmaceutical
company to conduct a European clinical trial to assess the efficacy
of TFC-1067 at .4%. The 12-week study was completed successfully in
February. Results are being consolidated into a final report to be
released within the next few weeks.
"Rodan + Fields' use of TFC-1067 in their new REVERSE Targeted
Dark Spot Corrector after extensive testing is the strongest
validation of our technology to date. Rodan + Fields demand product
excellence and innovation for their customers. TFC-1067 is the
basis for a product that can uniquely brighten dark spots without
leaving a halo effect," said Dr Howard
Verrico, CEO of Sirona Biochem. "Our long-term goal is to
provide an effective alternative to hydroquinone for those seeking
a solution for skin discoloration. With this launch, we have proven
that we can take a compound from the laboratory through clinical
trials to large-scale production and integration into a commercial
product. This validates our business model and we aim to follow the
same path exactly for our entire pipeline. This transformative
event is only the beginning as Sirona Biochem evolves into a
profitable broadly diversified large company."
|
*Based on an
8-week U.S. clinical and consumer study. Results may vary depending
on multiple factors: age, gender, skin type and condition,
concomitant products used, health history, location, lifestyle and
diet.
|
About TFC-1067
TFC-1067, Sirona's proprietary compound, is proving to be
superior to current actives on the market, safe and free of
hydroquinone. The compound has undergone extensive testing, both
clinical and preclinical, including a double blinded study for
dyschromia in the USA and a recent
trial in the EU for higher dose. Clinical results have shown the
compound to be superior to hydroquinone in the treatment of
dyschromia with no adverse side effects.
About Rodan + Fields
Founded by Stanford-trained
dermatologists Dr. Katie Rodan and
Dr. Kathy Fields, Rodan + Fields was
launched in 2002 with the mission of giving consumers the best skin
of their lives. The brand is a result of the Doctors' belief that
healthy skin empowers people to feel confident. Born in the digital
era and designed to directly reach consumers where they live and
shop via mobile and social networks, Rodan + Fields is disrupting
the industry with its regimen-based skincare and powerful
Independent Consultant community.
For more information, please visit www.rodanandfields.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.